Debulking Surgery Should Come Soon After NACT in Ovarian Cancer Debulking Surgery Should Come Soon After NACT in Ovarian Cancer
Survival outcomes were better when debulking surgery was performed within 4 weeks of neoadjuvant chemotherapy (NACT), according to a study that was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' Remarkable' Results: Some Patients With Breast Cancer Skip Surgery'Remarkable' Results: Some Patients With Breast Cancer Skip Surgery
' Remarkable ' results from a small study suggests that some patients with breast cancer who respond exceptionally well to neoadjuvant systemic therapy may be able skip surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
' Remarkable' Result: Some Patients With Breast Cancer Skip Surgery'Remarkable' Result: Some Patients With Breast Cancer Skip Surgery
' Remarkable ' results from a small study suggests that some patients with breast cancer who respond exceptionally well to neoadjuvant systemic therapy may be able skip surgery.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 4, 2022 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 28, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Surgery, Journal, Source Type: news
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
FRIDAY, Oct. 28, 2022 -- For patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab and nivolumab combination immunotherapy results in a 57 percent pathologic complete response rate, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 28, 2022 Category: Pharmaceuticals Source Type: news
Is pCR a Reliable Survival Surrogate in Breast Cancer Trials? Is pCR a Reliable Survival Surrogate in Breast Cancer Trials?
Pathologic complete response (pCR) is not a reliable surrogate endpoint in neoadjuvant therapy trials for early breast cancer; alternatives are needed, researchers said.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Elimination of Surgery Explored for Selected Breast Cancer Patients
Surgery eliminated in highly selected patients with image - guided vacuum - assisted core biopsy - determined pathological complete response to neoadjuvant systemic therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 27, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Radiology, Journal, Source Type: news
Elimination of Surgery Explored for Selected Breast Cancer Patients
THURSDAY, Oct. 27, 2022 -- For highly selected patients with breast cancer, eliminating surgery may be feasible for neoadjuvant systemic therapy (NST) responders identified with an image-guided vacuum-assisted core biopsy (VACB), according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 27, 2022 Category: Pharmaceuticals Source Type: news
Study Suggests Potential to Skip Surgery for Selected Breast Cancer Patients
(MedPage Today) -- Women who chose not to have surgery after a pathologic complete response (pCR) to neoadjuvant therapy for early HER2-positive or triple-negative breast cancer (TNBC) had no recurrences during the first 2 years of follow-up, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 26, 2022 Category: Hematology Source Type: news
Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy
Drs Jacob Sands and Benjamin Levy discuss the management of lung cancer with neoadjuvant and adjuvant therapy and the potential impact of current clinical trials.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Response to Neoadjuvant Chemo for Breast Cancer Varies by Sex
Men have lower rates of pathologic complete response than women across tumor subtypes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Journal, Source Type: news
Neoadjuvant CRT Tied to Survival Benefit in Older Rectal Cancer Patients
(MedPage Today) -- Neoadjuvant chemoradiation therapy (CRT) followed by surgical resection was associated with a survival benefit in elderly patients with locally advanced rectal cancer compared with other treatment sequences, according to a retrospective... (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 6, 2022 Category: Radiology Source Type: news
Surgery Now or Wait? Tool Gauges Rectal Cancer Recurrence Risk Surgery Now or Wait? Tool Gauges Rectal Cancer Recurrence Risk
A dynamic risk calculator estimates the risk of rectal cancer recurrence over time following neoadjuvant therapy to help patients decide between surgery and watch-and-wait surveillance.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 6, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Response to Neoadjuvant Chemo for Breast Cancer Varies by Sex
THURSDAY, Oct. 6, 2022 -- Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2022 Category: Pharmaceuticals Source Type: news
